Analysts' ratings for Simulations Plus (NASDAQ:SLP) over the last quarter vary from bullish to bearish, as provided by 4 analysts.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Simulations Plus, presenting an average target of $56.0, a high estimate of $65.00, and a low estimate of $47.00. This upward trend is evident, with the current average reflecting a 3.7% increase from the previous average price target of $54.00.

Decoding Analyst Ratings: A Detailed Look

A comprehensive examination of how financial experts perceive Simulations Plus is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Capture valuable insights into Simulations Plus's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Simulations Plus analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Simulations Plus Better

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.

A Deep Dive into Simulations Plus's Financials

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Simulations Plus displayed positive results in 3 months. As of 31 May, 2024, the company achieved a solid revenue growth rate of approximately 14.23%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.92%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Simulations Plus's ROE excels beyond industry benchmarks, reaching 1.75%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Simulations Plus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.62%, the company showcases efficient use of assets and strong financial health.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.